CMRX

Chimerix, Inc. (CMRX) | Rumor.io

Chimerix

CMRX

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about CMRX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Mar 10

Chimerix, Inc. ($CMRX) saw a significant buy order at the high of the day.
The company's five-year chart appears to be showing a dramatic trend.
$CMRX is expected to see a potential run-up in price.

Generated by AI

Sentiment

Of the messages about CMRX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	88.57% -1.63
Bearish	—	—	—	11.43% +1.63

Bullish· Mar 5

$CMRX has been acquired by JAZZ, resulting in a significant return for shareholders.
The acquisition price of $935 million represents a 600% premium over the asset's lows.
The deal highlights the potential for accelerated approval designated neuro assets to attract high bids.

Bearish· Mar 5

Chimerix, Inc. ($CMRX) is undervalued, with some investors considering it a "steal" at its current price, suggesting it may have more room to grow.
The company's acquisition by Jazz Pharmaceuticals ($JAZZ) at a 70% premium to its current price may not be a positive outcome for Chimerix investors, as it could be seen as a low valuation.
Chimerix's recent performance has been disappointing, with some investors expressing frustration and anger at the company's handling of its potential, which they believe has been undervalued.

Generated by AI

Topics

Of the messages about CMRX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	96.57%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	3.43%

Earnings· Nov 8

Chimerix, Inc. ($CMRX) reported a loss of $0.37, beating consensus estimates of a loss of $0.43 per share.
The company will host its Q3 earnings call today at 8:30 AM Eastern, which can be streamed live or replayed later.
Chimerix, Inc. ($CMRX) beat earnings per share loss estimates by $0.06 and also exceeded revenue expectations.

Analysts· Feb 22

Chimerix's ($CMRX) overweight rating has been reiterated at Piper Jaffray, with a price target of $18.00.
Citigroup Inc. has downgraded Chimerix ($CMRX) to neutral, while Morgan Stanley has downgraded it to underweight with a price target of $5.00.
Analysts at Citi and Morgan Stanley have expressed concerns about Chimerix's ($CMRX) drug not being effective against BK virus, leading to downgrades and reduced price targets.

Announcements· Mar 5

Chimerix, Inc. ($CMRX) has been acquired by Jazz Pharmaceuticals for $8.55 per share in cash, representing a total consideration of approximately $935 million.
The acquisition is expected to further diversify Jazz Pharmaceuticals' oncology portfolio and is subject to customary closing conditions, including the tender of a majority of the outstanding shares of Chimerix's voting common stock.
Chimerix's lead clinical asset, dordaviprone, is a novel first-in-class small molecule treatment in development for H3 K27M-mutant diffuse glioma, a rare, high-grade brain tumor that most commonly affects children and young adults.

Technical Analysis· Dec 10

$CMRX is breaking 2.90 resistance and has potential to reach $3.30 or more.
The stock has formed an inverse head and shoulders pattern and is showing signs of a possible breakout.
The price has been in a coiling pattern, with extension targets at $2.65, $2.90-$3, and $3.30+, and support at $2.25.

Generated by AI

Community

Of the messages about CMRX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	75.69%
Newcomers	—	—	—	24.31%

Regulars· Feb 18

$CMRX's PDUFA target action date is August 18, 2025, with a priority review in place, increasing the likelihood of an earlier approval.
The company's strong relationships with $NVS, a potential acquirer, may influence its future plans, with some participants speculating that $NVS might acquire $CMRX.
The upcoming Ph1 206 data in Q2, Ph3 interim 1st-line data in Q3, and August PDUFA date are seen as major catalysts for $CMRX's stock price, potentially driving it to double digits this year.

Newcomers· Dec 12

$CMRX needs to retest 3.25 to set up a potential trade, with the stock's recent performance drawing comparisons to $RGTI.
The company's news about the FDA's accelerated approval pathway for its Viaskin Peanut Patch has sparked interest, with some drawing parallels to a similar announcement made by $CMRX.
The author made a small trade on $CMRX, citing BN as a thank-you.

Generated by AI

Also Discussed

Investors talking about CMRX also mention

#	Name	Attention
1	SIGA Technologies Inc.SIGA	0%new
2	Emergent BioSolutions Inc.EBS	0%new
3	Lakeland Industries, Inc.LAKE	0%0
4	GeoVax Labs, Inc.GOVX	0%+0
5	PTC Therapeutics, Inc.PTCT	0%new
6	XOMA CorporationXOMA	0%0
7	Agios Pharmaceuticals, Inc.AGIO	0%0
8	RGLS - Regulus Therapeutics Inc.	——
9	BDSI - BioDelivery Sciences International, Inc.	——
10	MACK - Merrimack Pharmaceuticals, Inc.	——

Chimerix, Inc.

Location

Social

What share of all stock conversation is about CMRX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Mar 10

Chimerix, Inc. ($CMRX) saw a significant buy order at the high of the day.
The company's five-year chart appears to be showing a dramatic trend.
$CMRX is expected to see a potential run-up in price.

Generated by AI

Sentiment

Of the messages about CMRX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	88.57% -1.63
Bearish	—	—	—	11.43% +1.63

Bullish· Mar 5

$CMRX has been acquired by JAZZ, resulting in a significant return for shareholders.
The acquisition price of $935 million represents a 600% premium over the asset's lows.
The deal highlights the potential for accelerated approval designated neuro assets to attract high bids.

Bearish· Mar 5

Chimerix, Inc. ($CMRX) is undervalued, with some investors considering it a "steal" at its current price, suggesting it may have more room to grow.
The company's acquisition by Jazz Pharmaceuticals ($JAZZ) at a 70% premium to its current price may not be a positive outcome for Chimerix investors, as it could be seen as a low valuation.
Chimerix's recent performance has been disappointing, with some investors expressing frustration and anger at the company's handling of its potential, which they believe has been undervalued.

Generated by AI

Topics

Of the messages about CMRX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	96.57%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	3.43%

Earnings· Nov 8

Chimerix, Inc. ($CMRX) reported a loss of $0.37, beating consensus estimates of a loss of $0.43 per share.
The company will host its Q3 earnings call today at 8:30 AM Eastern, which can be streamed live or replayed later.
Chimerix, Inc. ($CMRX) beat earnings per share loss estimates by $0.06 and also exceeded revenue expectations.

Analysts· Feb 22

Chimerix's ($CMRX) overweight rating has been reiterated at Piper Jaffray, with a price target of $18.00.
Citigroup Inc. has downgraded Chimerix ($CMRX) to neutral, while Morgan Stanley has downgraded it to underweight with a price target of $5.00.
Analysts at Citi and Morgan Stanley have expressed concerns about Chimerix's ($CMRX) drug not being effective against BK virus, leading to downgrades and reduced price targets.

Announcements· Mar 5

Chimerix, Inc. ($CMRX) has been acquired by Jazz Pharmaceuticals for $8.55 per share in cash, representing a total consideration of approximately $935 million.
The acquisition is expected to further diversify Jazz Pharmaceuticals' oncology portfolio and is subject to customary closing conditions, including the tender of a majority of the outstanding shares of Chimerix's voting common stock.
Chimerix's lead clinical asset, dordaviprone, is a novel first-in-class small molecule treatment in development for H3 K27M-mutant diffuse glioma, a rare, high-grade brain tumor that most commonly affects children and young adults.

Technical Analysis· Dec 10

$CMRX is breaking 2.90 resistance and has potential to reach $3.30 or more.
The stock has formed an inverse head and shoulders pattern and is showing signs of a possible breakout.
The price has been in a coiling pattern, with extension targets at $2.65, $2.90-$3, and $3.30+, and support at $2.25.

Generated by AI

Community

Of the messages about CMRX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	75.69%
Newcomers	—	—	—	24.31%

Regulars· Feb 18

$CMRX's PDUFA target action date is August 18, 2025, with a priority review in place, increasing the likelihood of an earlier approval.
The company's strong relationships with $NVS, a potential acquirer, may influence its future plans, with some participants speculating that $NVS might acquire $CMRX.
The upcoming Ph1 206 data in Q2, Ph3 interim 1st-line data in Q3, and August PDUFA date are seen as major catalysts for $CMRX's stock price, potentially driving it to double digits this year.

Newcomers· Dec 12

$CMRX needs to retest 3.25 to set up a potential trade, with the stock's recent performance drawing comparisons to $RGTI.
The company's news about the FDA's accelerated approval pathway for its Viaskin Peanut Patch has sparked interest, with some drawing parallels to a similar announcement made by $CMRX.
The author made a small trade on $CMRX, citing BN as a thank-you.

Generated by AI

Chimerix

Social

Mar 10

Sentiment

Bullish· Mar 5

Bearish· Mar 5

Topics

Earnings· Nov 8

Analysts· Feb 22

Announcements· Mar 5

Technical Analysis· Dec 10

Community

Regulars· Feb 18

Newcomers· Dec 12

Also Discussed

Chimerix, Inc.

Company Information

Location

Also Discussed

Social

Mar 10

Sentiment

Bullish· Mar 5

Bearish· Mar 5

Topics

Earnings· Nov 8

Analysts· Feb 22

Announcements· Mar 5

Technical Analysis· Dec 10

Community

Regulars· Feb 18

Newcomers· Dec 12